Further analysis using FACS to separate GFP-positive circulating cancer cells from the blood showed a significantly higher number of circulating 22Rv1 cells with ZMYND11 knockdown compared to controls (Fig. 2h). This evidence concerns the gene ZMYND11 and cancer.